# US 2012/0252835 A1 · Stable temsirolimus composition and process of preparing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252835 A1
- Document ID: US20120252835A1
- Status: Published application
- Kind: A1
- Application number: 13/431,279
- Filed: 2012-03-27
- Published: 2012-10-04
- Earliest claimed: 2011-04-01
- Assignees: Astron Research Limited
- Inventors: Harsh RAJPUT; Sandeep MEHTA; Pankaj PATEL; Bhavesh PATEL; Ashish SEHGAL; Jayanta Kumar MANDAL
- Web page: https://patentgrep.com/patent/US20120252835A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure describes a stable composition of Temsirolimus for parenteral administration. The composition includes BHA or BHT as anti-oxidants and alcoholic solvent. The pH of the composition is below 5.0. The composition also can include a chelating agent and/or a surfactant. A method of producing the composition is also described.

## Claims

### Claim 1

A stable pharmaceutical composition of Temsirolimus for parenteral administration, comprising:
Temsirolimus as an active pharmaceutical ingredient (API);
at least one anti-oxidant selected from the group consisting of butylatedhydroxyanisole (BHA) and butylatedhydroxytoluene (BHT); and
an alcoholic solvent,
wherein a pH of the composition is below about 5.0.

### Claim 2 (depends on 1)

The composition according to claim 1, wherein the pH of said composition is more than 3.5.

### Claim 3 (depends on 1)

The composition according to claim 1, wherein the API is present in the composition in an amount of about 0.05 mg/ml to about 50 mg/ml.

### Claim 4 (depends on 1)

The composition according to claim 1, wherein the at least one anti-oxidant is present in an amount of about 0.0002 to about 0.002% of the composition.

### Claim 5 (depends on 1)

The composition according to claim 1, wherein the alcoholic solvent is at least one selected from the group comprising ethanol, polyethylene glycol and propylene glycol.

### Claim 6 (depends on 1)

The composition according to claim 1, further comprising a diluent solvent.

### Claim 7 (depends on 6)

The composition according to claim 6, wherein the diluent solvent is at least one selected from the group comprising water, ethanol, polyethylene glycol, propylene glycol and polysorbates.

### Claim 8 (depends on 1)

The composition according to claim 1, further comprising a chelating agent.

### Claim 9 (depends on 8)

The composition according to claim 8, wherein the chelating agent is at least one selected from the group comprising citric acid, ascorbic acid, acetic acid and ethylene diaminetetraacetic acid (EDTA).

### Claim 10 (depends on 1)

The composition according to claim 1, further comprising a surfactant.

### Claim 11 (depends on 10)

The composition according to claim 10, wherein the surfactant is at least one selected from the group comprising a bile acid, ethoxylated vegetable oil, and polysorbates.

### Claim 12 (depends on 1)

The composition according to claim 1, wherein the composition is stable such that an assay percentage of Temsirolimus after storage of the composition does not vary by more than 10% of an initial assay percentage, and an amount of total impurities excluding Isomer C in the composition is not more than 3% after storage of the composition.

### Claim 13 (depends on 12)

The composition according to claim 12, wherein the storage conditions are 2-8° C. or 25° C. for a time period of at least three months.

### Claim 14 (depends on 1)

The composition according claim 1, wherein the composition is stable such that the composition is a clear and colorless solution after storage of the composition.

### Claim 15 (depends on 14)

The composition according to claim 14, wherein the storage conditions are 2-8° C. or 25° C. for a time period of at least three months.

### Claim 16 (depends on 1)

The composition according to claim 1, further comprising an infusion solution.

### Claim 17 (depends on 16)

The composition according to claim 16, wherein the infusion solution is at least one selected from the group consisting of sodium chloride and dextrose.

### Claim 18

A process for preparing a stable pharmaceutical composition of Temsirolimus for parenteral administration, comprising:
a) preparing a solution of an anti-oxidant in a co-solvent system comprising an alcoholic solvent, the anti-oxidant being at least one selected from the group consisting of butylatedhydroxyanisole (BHA) and butylatedhydroxytoluene (BHT) and the alcoholic solvent being at least one selected from the group comprising ethanol, polyethylene glycol and propylene glycol; and
b) adding Temsirolimus and optionally a chelating agent to the solution prepared in (a), the chelating agent being at least one selected from the group comprising citric acid, ascorbic acid, acetic acid and ethylenediaminetetraacetic acid (EDTA),
wherein a pH of the solution obtained in (b) is below about 5.0.

### Claim 19 (depends on 18)

The process according to claim 18, comprising mixing a diluent solvent that is at least one selected from the group comprising water, ethanol, polyethylene glycol, propylene glycol and polysorbates.
